Pages that link to "Q24243992"
Jump to navigation
Jump to search
The following pages link to 20 µg versus >20 µg estrogen combined oral contraceptives for contraception (Q24243992):
Displaying 8 items.
- Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne, and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome (Q24246247) (← links)
- Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome (Q24246323) (← links)
- An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest (Q28263416) (← links)
- User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 microg (Yasminelle) in clinical practice: a multi-country, questionnaire-based study (Q46109234) (← links)
- Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg. (Q47170985) (← links)
- Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates (Q49288581) (← links)
- Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study. (Q55331272) (← links)
- Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives? (Q59797032) (← links)